Navidea Biopharmaceuticals, Inc. (NAVB)
USD 0.0
(16.67%)
USD 0.0
(16.67%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2022 | 1.87 Million USD | 9125.72% |
| 2021 | 20.28 Thousand USD | -93.15% |
| 2020 | 296 Thousand USD | -42.23% |
| 2019 | 512.34 Thousand USD | 9.36% |
| 2018 | 468.49 Thousand USD | -99.92% |
| 2017 | 588.09 Million USD | 5999.79% |
| 2016 | 9.64 Million USD | -84.13% |
| 2015 | 60.74 Million USD | 105.65% |
| 2014 | 29.53 Million USD | 25.31% |
| 2013 | 23.57 Million USD | 240.15% |
| 2012 | 6.93 Million USD | 7.34% |
| 2011 | 6.45 Million USD | 0.0% |
| 2010 | - USD | -100.0% |
| 2009 | 10.94 Million USD | 84.47% |
| 2008 | 5.93 Million USD | 11.82% |
| 2007 | 5.3 Million USD | 8.75% |
| 2006 | 4.87 Million USD | -18.76% |
| 2005 | 6 Million USD | 8.76% |
| 2004 | 5.52 Million USD | 1053.23% |
| 2003 | 478.81 Thousand USD | 8886.69% |
| 2002 | 5328.00 USD | -73.37% |
| 2001 | 20.01 Thousand USD | -39.22% |
| 2000 | 32.92 Thousand USD | -97.49% |
| 1999 | 1.31 Million USD | 743.52% |
| 1998 | 155.81 Thousand USD | -92.47% |
| 1997 | 2.06 Million USD | 105.08% |
| 1996 | 1 Million USD | -8.29% |
| 1995 | 1.1 Million USD | -8.33% |
| 1994 | 1.2 Million USD | 1100.0% |
| 1993 | 100 Thousand USD | 0.0% |
| 1992 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 Q3 | 269.00 USD | -49.63% |
| 2023 Q1 | 1.96 Million USD | 4.97% |
| 2023 Q2 | 534.00 USD | -99.97% |
| 2022 Q3 | 1.79 Million USD | 148.17% |
| 2022 Q2 | 722.36 Thousand USD | 6293.19% |
| 2022 Q1 | 11.29 Thousand USD | -44.31% |
| 2022 FY | 1.87 Million USD | 9125.72% |
| 2022 Q4 | 1.87 Million USD | 4.41% |
| 2021 Q1 | 209.43 Thousand USD | -29.25% |
| 2021 Q2 | 120.47 Thousand USD | -42.48% |
| 2021 Q3 | 29.03 Thousand USD | -75.9% |
| 2021 Q4 | 20.28 Thousand USD | -30.13% |
| 2021 FY | 20.28 Thousand USD | -93.15% |
| 2020 Q1 | 513.7 Thousand USD | 0.26% |
| 2020 Q3 | 380.23 Thousand USD | -12.45% |
| 2020 FY | 296 Thousand USD | -42.23% |
| 2020 Q4 | 296 Thousand USD | -22.15% |
| 2020 Q2 | 434.32 Thousand USD | -15.45% |
| 2019 Q3 | 575.06 Thousand USD | -6.3% |
| 2019 Q1 | 685.98 Thousand USD | 46.42% |
| 2019 Q2 | 613.75 Thousand USD | -10.53% |
| 2019 FY | 512.34 Thousand USD | 9.36% |
| 2019 Q4 | 512.34 Thousand USD | -10.91% |
| 2018 Q4 | 468.49 Thousand USD | -3.9% |
| 2018 FY | 468.49 Thousand USD | -99.92% |
| 2018 Q1 | 572.61 Thousand USD | 0.0% |
| 2018 Q2 | 479.56 Thousand USD | -16.25% |
| 2018 Q3 | 487.5 Thousand USD | 1.65% |
| 2017 Q2 | 588.9 Thousand USD | 0.0% |
| 2017 Q1 | - USD | -100.0% |
| 2017 Q4 | - USD | -100.0% |
| 2017 Q3 | 629.44 Thousand USD | 6.88% |
| 2017 FY | 588.09 Million USD | 5999.79% |
| 2016 Q2 | 9.51 Million USD | -10.8% |
| 2016 Q1 | 10.67 Million USD | -82.43% |
| 2016 Q4 | 9.64 Million USD | -8.61% |
| 2016 Q3 | 10.54 Million USD | 10.82% |
| 2016 FY | 9.64 Million USD | -84.13% |
| 2015 Q4 | 60.74 Million USD | -0.33% |
| 2015 Q1 | 29.3 Million USD | -0.79% |
| 2015 FY | 60.74 Million USD | 105.65% |
| 2015 Q2 | 58.83 Million USD | 100.76% |
| 2015 Q3 | 60.94 Million USD | 3.59% |
| 2014 Q1 | 30.93 Million USD | 31.25% |
| 2014 FY | 29.53 Million USD | 25.31% |
| 2014 Q2 | 30.43 Million USD | -1.62% |
| 2014 Q4 | 29.53 Million USD | -0.73% |
| 2014 Q3 | 29.75 Million USD | -2.24% |
| 2013 Q2 | 27.22 Million USD | 165.86% |
| 2013 Q3 | 26.08 Million USD | -4.18% |
| 2013 FY | 23.57 Million USD | 240.15% |
| 2013 Q4 | 23.57 Million USD | -9.64% |
| 2013 Q1 | 10.24 Million USD | 47.77% |
| 2012 Q3 | 3.59 Million USD | -15.09% |
| 2012 Q1 | 4.84 Million USD | -24.9% |
| 2012 Q4 | 6.93 Million USD | 92.84% |
| 2012 FY | 6.93 Million USD | 7.34% |
| 2012 Q2 | 4.23 Million USD | -12.71% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q4 | 6.45 Million USD | 0.0% |
| 2011 FY | 6.45 Million USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2010 Q1 | 10.95 Million USD | -0.13% |
| 2010 FY | - USD | -100.0% |
| 2010 Q4 | - USD | -100.0% |
| 2010 Q3 | 12.19 Thousand USD | -9.06% |
| 2010 Q2 | 13.4 Thousand USD | -99.88% |
| 2009 FY | 10.94 Million USD | 84.47% |
| 2009 Q1 | 6.02 Million USD | 1.6% |
| 2009 Q4 | 10.96 Million USD | 0.18% |
| 2009 Q3 | 10.94 Million USD | 77.04% |
| 2009 Q2 | 6.18 Million USD | 2.55% |
| 2008 Q1 | 5.4 Million USD | 1.92% |
| 2008 Q4 | 5.93 Million USD | 2.78% |
| 2008 Q2 | 5.62 Million USD | 3.92% |
| 2008 FY | 5.93 Million USD | 11.82% |
| 2008 Q3 | 5.77 Million USD | 2.72% |
| 2007 Q4 | 5.3 Million USD | 151.24% |
| 2007 FY | 5.3 Million USD | 8.75% |
| 2007 Q1 | 3.38 Million USD | -30.6% |
| 2007 Q2 | 3.48 Million USD | 2.91% |
| 2007 Q3 | 2.11 Million USD | -39.4% |
| 2006 Q2 | 6.27 Million USD | 2.28% |
| 2006 Q1 | 6.13 Million USD | 2.19% |
| 2006 FY | 4.87 Million USD | -18.76% |
| 2006 Q4 | 4.87 Million USD | -24.05% |
| 2006 Q3 | 6.42 Million USD | 2.34% |
| 2005 Q2 | 5.76 Million USD | 2.01% |
| 2005 Q4 | 6 Million USD | 2.16% |
| 2005 FY | 6 Million USD | 8.76% |
| 2005 Q1 | 5.64 Million USD | 2.26% |
| 2005 Q3 | 5.87 Million USD | 2.06% |
| 2004 Q3 | 33.9 Thousand USD | -9.38% |
| 2004 FY | 5.52 Million USD | 1053.23% |
| 2004 Q1 | 121.63 Thousand USD | -74.6% |
| 2004 Q2 | 37.41 Thousand USD | -69.24% |
| 2004 Q4 | 5.52 Million USD | 16187.03% |
| 2003 FY | 478.81 Thousand USD | 8886.69% |
| 2003 Q4 | 478.81 Thousand USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q2 | - USD | -100.0% |
| 2003 Q1 | 1354.00 USD | -74.59% |
| 2002 Q4 | 5328.00 USD | -41.95% |
| 2002 Q1 | 16.51 Thousand USD | -17.47% |
| 2002 Q2 | 12.9 Thousand USD | -21.86% |
| 2002 Q3 | 9178.00 USD | -28.88% |
| 2002 FY | 5328.00 USD | -73.37% |
| 2001 Q4 | 20.01 Thousand USD | -14.47% |
| 2001 Q1 | 29.85 Thousand USD | -9.34% |
| 2001 FY | 20.01 Thousand USD | -39.22% |
| 2001 Q2 | 26.67 Thousand USD | -10.64% |
| 2001 Q3 | 23.39 Thousand USD | -12.29% |
| 2000 Q3 | 35.9 Thousand USD | -55.4% |
| 2000 Q1 | 55.33 Thousand USD | -20.95% |
| 2000 FY | 32.92 Thousand USD | -97.49% |
| 2000 Q4 | 32.92 Thousand USD | -8.29% |
| 2000 Q2 | 80.5 Thousand USD | 45.49% |
| 1999 Q1 | 100 Thousand USD | -35.82% |
| 1999 Q3 | 80 Thousand USD | -20.0% |
| 1999 Q4 | 70 Thousand USD | -12.5% |
| 1999 FY | 1.31 Million USD | 743.52% |
| 1999 Q2 | 100 Thousand USD | 0.0% |
| 1998 Q2 | 4.6 Million USD | 4.55% |
| 1998 FY | 155.81 Thousand USD | -92.47% |
| 1998 Q4 | 155.81 Thousand USD | -96.68% |
| 1998 Q1 | 4.4 Million USD | 112.68% |
| 1998 Q3 | 4.7 Million USD | 2.17% |
| 1997 Q2 | 1.9 Million USD | 46.15% |
| 1997 Q3 | 2 Million USD | 5.26% |
| 1997 Q4 | 2.06 Million USD | 3.44% |
| 1997 Q1 | 1.3 Million USD | 28.87% |
| 1997 FY | 2.06 Million USD | 105.08% |
| 1996 Q4 | 1 Million USD | 0.88% |
| 1996 Q1 | 600 Thousand USD | -45.45% |
| 1996 Q2 | 600 Thousand USD | 0.0% |
| 1996 Q3 | 1 Million USD | 66.67% |
| 1996 FY | 1 Million USD | -8.29% |
| 1995 Q2 | 200 Thousand USD | 0.0% |
| 1995 Q4 | 1.1 Million USD | -8.33% |
| 1995 Q1 | 200 Thousand USD | -83.33% |
| 1995 FY | 1.1 Million USD | -8.33% |
| 1995 Q3 | 1.2 Million USD | 500.0% |
| 1994 FY | 1.2 Million USD | 1100.0% |
| 1994 Q3 | 400 Thousand USD | 0.0% |
| 1994 Q4 | 1.2 Million USD | 200.0% |
| 1994 Q2 | 400 Thousand USD | 100.0% |
| 1994 Q1 | 200 Thousand USD | 100.0% |
| 1993 Q4 | 100 Thousand USD | 0.0% |
| 1993 FY | 100 Thousand USD | 0.0% |
| 1993 Q1 | - USD | 0.0% |
| 1993 Q2 | - USD | 0.0% |
| 1993 Q3 | 100 Thousand USD | 0.0% |
| 1992 FY | - USD | 0.0% |
| 1992 Q3 | - USD | 0.0% |
| 1992 Q4 | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| America Great Health | 1.12 Million USD | -66.65% |
| Ampio Pharmaceuticals, Inc. | - USD | -Infinity% |
| Aridis Pharmaceuticals, Inc. | 1.29 Million USD | -44.87% |
| Biora Therapeutics, Inc. | 43.73 Million USD | 95.72% |
| Bio-Path Holdings, Inc. | 10 Thousand USD | -18617.15% |
| Better Therapeutics, Inc. | 10.34 Million USD | 81.912% |
| Calithera Biosciences, Inc. | 136 Thousand USD | -1276.261% |
| Comera Life Sciences Holdings, Inc. | 120.3 Thousand USD | -1455.847% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | - USD | -Infinity% |
| Eloxx Pharmaceuticals, Inc. | 8.69 Million USD | 78.466% |
| Evelo Biosciences, Inc. | 48.87 Million USD | 96.171% |
| Evolutionary Genomics, Inc. | 3.74 Million USD | 50.004% |
| Finch Therapeutics Group, Inc. | 28.4 Million USD | 93.41% |
| Galera Therapeutics, Inc. | 151.04 Million USD | 98.761% |
| Innovation1 Biotech Inc. | 218.99 Thousand USD | -754.668% |
| Kiromic BioPharma, Inc. | 911.5 Thousand USD | -105.344% |
| Molecular Templates, Inc. | 9.74 Million USD | 80.787% |
| NexImmune, Inc. | - USD | -Infinity% |
| Orgenesis Inc. | 19.06 Million USD | 90.183% |
| Panbela Therapeutics, Inc. | 4.19 Million USD | 55.372% |
| Point of Care Nano-Technology, Inc. | - USD | -Infinity% |
| PaxMedica, Inc. Common Stock | - USD | -Infinity% |
| Scopus BioPharma Inc. | - USD | -Infinity% |
| Sorrento Therapeutics, Inc. | 104.33 Million USD | 98.206% |
| Statera Biopharma, Inc. | 11.43 Million USD | 83.626% |
| TRACON Pharmaceuticals, Inc. | 732 Thousand USD | -155.699% |
| Trevena, Inc. | 35.23 Million USD | 94.688% |
| Vaxxinity, Inc. | 13.26 Million USD | 85.887% |
| Vaccinex, Inc. | 26 Thousand USD | -7098.904% |
| Vicapsys Life Sciences, Inc. | - USD | -Infinity% |
| Viracta Therapeutics, Inc. | - USD | -Infinity% |
| ZIVO Bioscience, Inc. | - USD | -Infinity% |